 Ronina Covar
Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 77 | 2023 | 2295 | 5.540 |
Why?
| | Anti-Asthmatic Agents | 29 | 2021 | 395 | 3.020 |
Why?
| | Bronchial Provocation Tests | 6 | 2022 | 51 | 1.610 |
Why?
| | Bronchodilator Agents | 15 | 2019 | 252 | 1.500 |
Why?
| | Adrenal Cortex Hormones | 15 | 2022 | 565 | 1.430 |
Why?
| | Respiratory Sounds | 12 | 2022 | 125 | 1.250 |
Why?
| | Budesonide | 9 | 2016 | 89 | 1.120 |
Why?
| | Bronchial Hyperreactivity | 5 | 2018 | 111 | 1.060 |
Why?
| | Eosinophilia | 2 | 2023 | 218 | 0.840 |
Why?
| | Nedocromil | 5 | 2016 | 32 | 0.810 |
Why?
| | Albuterol | 10 | 2018 | 110 | 0.800 |
Why?
| | Administration, Inhalation | 22 | 2022 | 688 | 0.790 |
Why?
| | Glucocorticoids | 11 | 2019 | 594 | 0.790 |
Why?
| | Androstadienes | 7 | 2016 | 107 | 0.780 |
Why?
| | Fluticasone | 10 | 2019 | 90 | 0.770 |
Why?
| | Respiratory Function Tests | 13 | 2018 | 600 | 0.760 |
Why?
| | Lung | 8 | 2022 | 4060 | 0.740 |
Why?
| | Forced Expiratory Volume | 16 | 2022 | 531 | 0.660 |
Why?
| | Respiratory Mechanics | 1 | 2020 | 67 | 0.640 |
Why?
| | Anti-Inflammatory Agents | 10 | 2016 | 496 | 0.620 |
Why?
| | Leukotriene Antagonists | 6 | 2016 | 43 | 0.610 |
Why?
| | Mediastinal Emphysema | 1 | 2018 | 7 | 0.570 |
Why?
| | Nitric Oxide | 6 | 2023 | 915 | 0.550 |
Why?
| | Child | 49 | 2023 | 21935 | 0.490 |
Why?
| | Acetates | 7 | 2014 | 99 | 0.480 |
Why?
| | Double-Blind Method | 19 | 2021 | 1993 | 0.460 |
Why?
| | Quinolines | 7 | 2014 | 178 | 0.450 |
Why?
| | Marijuana Smoking | 1 | 2018 | 252 | 0.440 |
Why?
| | Eosinophils | 6 | 2023 | 332 | 0.430 |
Why?
| | Precision Medicine | 4 | 2021 | 429 | 0.400 |
Why?
| | Child, Preschool | 35 | 2022 | 11074 | 0.400 |
Why?
| | Sputum | 4 | 2023 | 311 | 0.400 |
Why?
| | Humans | 85 | 2023 | 137585 | 0.390 |
Why?
| | Adrenergic beta-Agonists | 4 | 2013 | 134 | 0.380 |
Why?
| | Cannabis | 1 | 2018 | 494 | 0.340 |
Why?
| | Phenotype | 4 | 2020 | 3196 | 0.340 |
Why?
| | Biomarkers | 10 | 2023 | 4149 | 0.330 |
Why?
| | Eicosapentaenoic Acid | 1 | 2010 | 39 | 0.330 |
Why?
| | Docosahexaenoic Acids | 1 | 2010 | 84 | 0.320 |
Why?
| | Salmeterol Xinafoate | 6 | 2019 | 41 | 0.320 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2021 | 1477 | 0.310 |
Why?
| | Adolescent | 31 | 2022 | 21513 | 0.310 |
Why?
| | Ibuprofen | 2 | 2021 | 84 | 0.290 |
Why?
| | Male | 53 | 2020 | 67762 | 0.290 |
Why?
| | Spirometry | 9 | 2022 | 281 | 0.270 |
Why?
| | Drug Therapy, Combination | 7 | 2016 | 1066 | 0.260 |
Why?
| | Female | 52 | 2020 | 73304 | 0.260 |
Why?
| | Breath Tests | 3 | 2023 | 87 | 0.260 |
Why?
| | Antioxidants | 1 | 2010 | 584 | 0.250 |
Why?
| | Disease Progression | 9 | 2018 | 2757 | 0.240 |
Why?
| | Treatment Outcome | 15 | 2019 | 10811 | 0.240 |
Why?
| | Pulmonary Ventilation | 1 | 2005 | 79 | 0.220 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2022 | 1040 | 0.220 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2005 | 201 | 0.210 |
Why?
| | Microbiota | 2 | 2023 | 762 | 0.210 |
Why?
| | Beclomethasone | 2 | 2015 | 27 | 0.210 |
Why?
| | Severity of Illness Index | 12 | 2021 | 2828 | 0.210 |
Why?
| | Ribonucleases | 1 | 2003 | 55 | 0.200 |
Why?
| | Mycobiome | 1 | 2023 | 9 | 0.200 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2005 | 323 | 0.200 |
Why?
| | Larynx | 1 | 2023 | 60 | 0.200 |
Why?
| | Respiration | 1 | 2003 | 199 | 0.190 |
Why?
| | Antigens, Dermatophagoides | 1 | 2022 | 10 | 0.190 |
Why?
| | Muscarinic Antagonists | 1 | 2022 | 29 | 0.190 |
Why?
| | Prospective Studies | 8 | 2023 | 7604 | 0.190 |
Why?
| | Azithromycin | 2 | 2015 | 100 | 0.190 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 350 | 0.180 |
Why?
| | Dietary Supplements | 2 | 2020 | 561 | 0.180 |
Why?
| | Airway Obstruction | 2 | 2022 | 162 | 0.180 |
Why?
| | Prednisone | 4 | 2016 | 240 | 0.180 |
Why?
| | Models, Biological | 1 | 2008 | 1783 | 0.180 |
Why?
| | Vitamin D Deficiency | 2 | 2020 | 186 | 0.170 |
Why?
| | Cholecalciferol | 1 | 2020 | 60 | 0.160 |
Why?
| | Infant | 15 | 2022 | 9465 | 0.160 |
Why?
| | Leukocyte Count | 4 | 2019 | 329 | 0.160 |
Why?
| | Methacholine Chloride | 3 | 2022 | 52 | 0.160 |
Why?
| | Cross-Over Studies | 6 | 2019 | 564 | 0.160 |
Why?
| | Mometasone Furoate | 1 | 2019 | 5 | 0.160 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 37 | 0.160 |
Why?
| | Tiotropium Bromide | 1 | 2019 | 19 | 0.150 |
Why?
| | Vitamins | 1 | 2020 | 185 | 0.150 |
Why?
| | Symbiosis | 1 | 2019 | 79 | 0.150 |
Why?
| | Minority Groups | 1 | 2021 | 266 | 0.150 |
Why?
| | Social Class | 1 | 2021 | 282 | 0.150 |
Why?
| | Population | 1 | 2018 | 35 | 0.150 |
Why?
| | Risk Factors | 8 | 2016 | 10388 | 0.140 |
Why?
| | Cyclopropanes | 7 | 2014 | 90 | 0.140 |
Why?
| | Acetaminophen | 2 | 2021 | 268 | 0.140 |
Why?
| | Education | 1 | 2018 | 108 | 0.140 |
Why?
| | Sulfides | 7 | 2014 | 99 | 0.140 |
Why?
| | Practice Guidelines as Topic | 2 | 2021 | 1587 | 0.130 |
Why?
| | Patient Selection | 1 | 2021 | 696 | 0.130 |
Why?
| | Benzyl Alcohols | 1 | 2016 | 2 | 0.130 |
Why?
| | Chlorobenzenes | 1 | 2016 | 9 | 0.130 |
Why?
| | Airway Remodeling | 1 | 2016 | 64 | 0.130 |
Why?
| | Child Care | 1 | 2016 | 32 | 0.120 |
Why?
| | Eczema | 2 | 2014 | 69 | 0.120 |
Why?
| | Tomography, X-Ray Computed | 3 | 2021 | 2691 | 0.120 |
Why?
| | Adult | 13 | 2023 | 37929 | 0.120 |
Why?
| | Anti-Bacterial Agents | 3 | 2015 | 1809 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2019 | 2057 | 0.120 |
Why?
| | Genetic Predisposition to Disease | 3 | 2016 | 2426 | 0.120 |
Why?
| | Bronchoconstrictor Agents | 2 | 2006 | 16 | 0.120 |
Why?
| | Cluster Analysis | 1 | 2016 | 499 | 0.110 |
Why?
| | Secondary Prevention | 1 | 2015 | 233 | 0.110 |
Why?
| | Lectins | 1 | 2014 | 49 | 0.110 |
Why?
| | Drug Administration Schedule | 5 | 2016 | 786 | 0.110 |
Why?
| | Adipokines | 1 | 2014 | 49 | 0.110 |
Why?
| | Teaching | 1 | 2016 | 224 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 322 | 0.110 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 250 | 0.100 |
Why?
| | Obesity | 2 | 2017 | 2992 | 0.100 |
Why?
| | Prognosis | 2 | 2016 | 4030 | 0.100 |
Why?
| | Food Hypersensitivity | 1 | 2016 | 183 | 0.100 |
Why?
| | Overweight | 1 | 2017 | 558 | 0.100 |
Why?
| | Virus Diseases | 1 | 2015 | 212 | 0.100 |
Why?
| | Body Height | 2 | 2011 | 199 | 0.100 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3284 | 0.100 |
Why?
| | Age Factors | 3 | 2016 | 3295 | 0.100 |
Why?
| | Disease Management | 1 | 2016 | 628 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 806 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2016 | 1050 | 0.090 |
Why?
| | Adaptive Clinical Trials as Topic | 2 | 2021 | 22 | 0.090 |
Why?
| | Multicenter Studies as Topic | 2 | 2018 | 310 | 0.090 |
Why?
| | Recurrence | 3 | 2016 | 1060 | 0.090 |
Why?
| | Genomics | 1 | 2016 | 795 | 0.090 |
Why?
| | Respiratory Tract Infections | 1 | 2015 | 390 | 0.090 |
Why?
| | Schools | 2 | 2018 | 461 | 0.090 |
Why?
| | Dexamethasone | 2 | 2005 | 368 | 0.090 |
Why?
| | Immunoglobulin E | 3 | 2015 | 342 | 0.090 |
Why?
| | Symptom Flare Up | 2 | 2020 | 39 | 0.080 |
Why?
| | Vital Capacity | 3 | 2022 | 311 | 0.080 |
Why?
| | Longitudinal Studies | 3 | 2016 | 2844 | 0.080 |
Why?
| | Young Adult | 4 | 2022 | 13209 | 0.080 |
Why?
| | Research Design | 3 | 2021 | 1139 | 0.080 |
Why?
| | Skin Tests | 2 | 2015 | 101 | 0.080 |
Why?
| | Drug Synergism | 2 | 2008 | 382 | 0.080 |
Why?
| | Growth | 2 | 2018 | 60 | 0.080 |
Why?
| | Time Factors | 3 | 2008 | 6828 | 0.080 |
Why?
| | Caregivers | 1 | 2016 | 877 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 3 | 2016 | 889 | 0.070 |
Why?
| | Hypersensitivity | 2 | 2018 | 257 | 0.070 |
Why?
| | Immunotherapy | 1 | 2012 | 641 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 1329 | 0.070 |
Why?
| | Adenosine Monophosphate | 1 | 2007 | 66 | 0.070 |
Why?
| | Respiratory Tract Diseases | 1 | 2008 | 184 | 0.070 |
Why?
| | Drug Resistance | 2 | 2018 | 169 | 0.060 |
Why?
| | Inflammation | 4 | 2005 | 2837 | 0.060 |
Why?
| | School Health Services | 1 | 2009 | 238 | 0.060 |
Why?
| | Drug Combinations | 2 | 2019 | 343 | 0.060 |
Why?
| | Regression Analysis | 1 | 2008 | 1024 | 0.060 |
Why?
| | Weight Gain | 1 | 2009 | 519 | 0.060 |
Why?
| | Cohort Studies | 3 | 2011 | 5742 | 0.060 |
Why?
| | Treatment Failure | 2 | 2020 | 356 | 0.060 |
Why?
| | Incidence | 2 | 2016 | 2804 | 0.060 |
Why?
| | Administration, Oral | 3 | 2013 | 816 | 0.060 |
Why?
| | Multivariate Analysis | 1 | 2008 | 1509 | 0.060 |
Why?
| | Bone Density | 1 | 2008 | 489 | 0.050 |
Why?
| | Biopsy | 2 | 2005 | 1129 | 0.050 |
Why?
| | Eosinophil Granule Proteins | 1 | 2003 | 21 | 0.050 |
Why?
| | Lymphocyte Activation | 2 | 2005 | 1142 | 0.050 |
Why?
| | Logistic Models | 2 | 2010 | 2074 | 0.050 |
Why?
| | Age of Onset | 3 | 2014 | 518 | 0.050 |
Why?
| | Age Distribution | 1 | 2004 | 392 | 0.050 |
Why?
| | Cross-Sectional Studies | 5 | 2015 | 5472 | 0.050 |
Why?
| | Sex Distribution | 1 | 2004 | 375 | 0.050 |
Why?
| | Health Status | 1 | 2008 | 792 | 0.050 |
Why?
| | Global Health | 1 | 2006 | 386 | 0.050 |
Why?
| | Statistics, Nonparametric | 1 | 2003 | 431 | 0.050 |
Why?
| | Clarithromycin | 1 | 2001 | 28 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2021 | 76 | 0.050 |
Why?
| | Research | 2 | 2022 | 451 | 0.050 |
Why?
| | Fungi | 1 | 2023 | 144 | 0.050 |
Why?
| | Bronchi | 1 | 2003 | 260 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2009 | 986 | 0.050 |
Why?
| | Trachea | 1 | 2023 | 237 | 0.040 |
Why?
| | Environmental Exposure | 1 | 2006 | 579 | 0.040 |
Why?
| | Blood Proteins | 1 | 2003 | 252 | 0.040 |
Why?
| | Medication Adherence | 2 | 2019 | 467 | 0.040 |
Why?
| | Cushing Syndrome | 1 | 2000 | 10 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2005 | 1483 | 0.040 |
Why?
| | Dyspnea | 1 | 2022 | 254 | 0.040 |
Why?
| | Adrenal Glands | 1 | 2000 | 78 | 0.040 |
Why?
| | Geography | 1 | 2021 | 200 | 0.040 |
Why?
| | Advisory Committees | 1 | 2021 | 219 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2021 | 271 | 0.040 |
Why?
| | Moraxella | 1 | 2019 | 5 | 0.040 |
Why?
| | Carnobacteriaceae | 1 | 2019 | 3 | 0.040 |
Why?
| | Streptococcus | 1 | 2019 | 28 | 0.040 |
Why?
| | Staphylococcus | 1 | 2019 | 76 | 0.040 |
Why?
| | Exercise Test | 1 | 2022 | 625 | 0.040 |
Why?
| | Nasal Mucosa | 1 | 2019 | 107 | 0.040 |
Why?
| | Allergens | 1 | 2022 | 409 | 0.040 |
Why?
| | Peak Expiratory Flow Rate | 1 | 2018 | 37 | 0.040 |
Why?
| | Animals | 2 | 2022 | 36940 | 0.040 |
Why?
| | Middle Aged | 6 | 2019 | 33479 | 0.040 |
Why?
| | Prevalence | 1 | 2005 | 2734 | 0.040 |
Why?
| | Absenteeism | 1 | 2018 | 49 | 0.040 |
Why?
| | United States | 3 | 2021 | 14841 | 0.030 |
Why?
| | Vitamin D | 1 | 2020 | 397 | 0.030 |
Why?
| | Netherlands | 1 | 2016 | 88 | 0.030 |
Why?
| | Sex Factors | 2 | 2016 | 2071 | 0.030 |
Why?
| | Placebo Effect | 1 | 2016 | 25 | 0.030 |
Why?
| | Bacteria | 1 | 2023 | 858 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2005 | 1996 | 0.030 |
Why?
| | Pharmacokinetics | 1 | 2016 | 29 | 0.030 |
Why?
| | Airway Resistance | 2 | 2006 | 41 | 0.030 |
Why?
| | Plethysmography | 2 | 2006 | 106 | 0.030 |
Why?
| | Exhalation | 1 | 2015 | 39 | 0.030 |
Why?
| | Fever | 1 | 2016 | 306 | 0.030 |
Why?
| | Anaphylaxis | 1 | 2016 | 105 | 0.030 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2014 | 19 | 0.030 |
Why?
| | Fluticasone-Salmeterol Drug Combination | 1 | 2014 | 12 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2015 | 186 | 0.030 |
Why?
| | Needs Assessment | 1 | 2016 | 376 | 0.030 |
Why?
| | Leukotriene E4 | 1 | 2013 | 27 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1236 | 0.030 |
Why?
| | Morbidity | 1 | 2014 | 324 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2014 | 218 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 1007 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 1062 | 0.020 |
Why?
| | Prednisolone | 1 | 2011 | 83 | 0.020 |
Why?
| | Colorado | 2 | 2014 | 4565 | 0.020 |
Why?
| | Hypertension | 1 | 2000 | 1295 | 0.020 |
Why?
| | Pain | 1 | 2016 | 756 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2016 | 1431 | 0.020 |
Why?
| | Curriculum | 1 | 2016 | 992 | 0.020 |
Why?
| | Body Mass Index | 1 | 2017 | 2389 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 2189 | 0.020 |
Why?
| | Poverty | 1 | 2012 | 521 | 0.020 |
Why?
| | Eosinophil Cationic Protein | 1 | 2008 | 10 | 0.020 |
Why?
| | Bone Diseases, Metabolic | 1 | 2008 | 63 | 0.020 |
Why?
| | Factor Analysis, Statistical | 1 | 2008 | 283 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 5131 | 0.020 |
Why?
| | Insurance, Health | 1 | 2009 | 283 | 0.020 |
Why?
| | Body Weight | 1 | 2011 | 985 | 0.020 |
Why?
| | Retrospective Studies | 3 | 2014 | 15657 | 0.020 |
Why?
| | Lung Volume Measurements | 1 | 2006 | 46 | 0.020 |
Why?
| | Birth Weight | 1 | 2009 | 516 | 0.020 |
Why?
| | Oscillometry | 1 | 2006 | 42 | 0.020 |
Why?
| | Biomedical Research | 1 | 2012 | 692 | 0.010 |
Why?
| | Inhibitory Concentration 50 | 1 | 2005 | 90 | 0.010 |
Why?
| | Respiratory Hypersensitivity | 1 | 2005 | 69 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2009 | 2031 | 0.010 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2000 | 3715 | 0.010 |
Why?
| | Basement Membrane | 1 | 2003 | 35 | 0.010 |
Why?
| | Fractures, Bone | 1 | 2008 | 380 | 0.010 |
Why?
| | Reference Values | 1 | 2005 | 816 | 0.010 |
Why?
| | Interleukins | 1 | 2005 | 250 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2005 | 1092 | 0.010 |
Why?
| | Immune Tolerance | 1 | 2005 | 363 | 0.010 |
Why?
| | Muscle, Smooth | 1 | 2003 | 155 | 0.010 |
Why?
| | Bronchoscopy | 1 | 2003 | 223 | 0.010 |
Why?
| | Steroids | 1 | 2002 | 167 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2005 | 1946 | 0.010 |
Why?
| | Gene Expression | 1 | 2005 | 1502 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2005 | 2833 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 5778 | 0.010 |
Why?
| | Pilot Projects | 1 | 2001 | 1710 | 0.010 |
Why?
| | Aged | 2 | 2005 | 23961 | 0.010 |
Why?
|
|
Covar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|